Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-20-055666 Act: 34 Size: 19 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 8.01 Accession Number: 0001104659-20-044193 Act: 34 Size: 23 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042583 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042578 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042579 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042580 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042581 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-042582 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-20-002547 Act: 34 Size: 14 MB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-20-032466 Act: 34 Size: 155 KB 网页链接